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LEADER 3—Lipase and Amylase Activity in Subjects With
Type 2 Diabetes
Baseline Data From Over 9000 Subjects in the LEADER Trial
William M. Steinberg, MD,* Michael A. Nauck, MD,† Bernard Zinman, MD,‡ Gilbert H. Daniels, MD,§
Richard M. Bergenstal, MD,k Johannes F.E. Mann, MD,¶ Lasse Steen Ravn, MD, PhD,# Alan C. Moses, MD,#
Mette Stockner, MD,# Florian M.M. Baeres, MD,# Steven P. Marso, MD,** and John B. Buse, MD, PhD††
on behalf of the LEADER Trial investigators
Objectives: This report from the LEADER (Liraglutide Effect and
Action in Diabetes: Evaluation of Cardiovascular Outcome Results)
trial describes baseline lipase and amylase activity in type 2 diabetic sub-
jects without acute pancreatitis symptoms before randomization to the
glucagonlike peptide analog liraglutide or placebo.
Methods: The LEADER is an international randomized placebo-
controlled trial evaluating the cardiovascular safety of liraglutide in 9340
type 2 diabetic patients at high cardiovascular risk. Fasting lipase and
amylase activity was assessed at baseline, before receiving liraglutide or
placebo, using a commercial assay (Roche) with upper limit of normal
values of 63 U/L for lipase and 100 U/L for amylase.
Results: Either or both enzymes were above the upper limit of normal in
22.7% of subjects; 16.6% (n = 1540) had an elevated lipase level (including
1.2% >3-fold elevated), and 11.8% (n = 1094) had an elevated amylase
level (including 0.2% >3-fold elevated). In multivariable regression models,
severely reduced kidney function was associated with the largest effect on in-
creasing activity of both. However, even among subjects with normal kidney
function, 12.2% and 7.7% had elevated lipase and amylase levels.
Conclusions: In this large study of type 2 diabetic patients, nearly 25%
had elevated lipase or amylase levels without symptoms of acute pancrea-
titis. The clinician must take these data into account when evaluating ab-
dominal symptoms in type 2 diabetic patients.
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S ubjects with type 2 diabetes are at increased risk of developingacute pancreatitis.1,2 Analyses from insurance claims databases
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estimate the incidence rate of acute pancreatitis in the diabetes pop-
ulation to be from 0.54 to 5.6 cases per 1000 patient-years.3,4 These
figures have been attributed to an increase in gallstone disease,
hypertriglyceridemia, and obesity, whereas drugs used to treat
type 2 diabetes may represent another factor potentially causing
an increase in acute pancreatitis.
Glucagonlike peptide (GLP-1) receptor agonists and dipeptidyl
peptidase (DPP-4) inhibitors (incretin-based therapies) are useful
agents in the treatment of type 2 diabetes. In a few case reports,
pharmacoepidemiologic studies,5–8 and adverse event reports
from the US Food and Drug Administration,9 an association be-
tween these drugs and acute pancreatitis has been suggested.
However, other studies have not found a similar association.3,10–12
Because of the questions raised about pancreatitis, current
studies using incretin-based therapies have measured serial amy-
lase and lipase activity at baseline and on therapy. Several studies
have reported elevated lipase and amylase activity at baseline
in a substantial minority of subjects with type 2 diabetes.13–18
Lipase activity has also been shown to rise after initiating use
of liraglutide, a GLP-1 analog, in subjects with type 2 diabetes
or obesity without diabetes.19 In an obese population without dia-
betes, lipase activity returned to baseline levels when liraglutide
was stopped.19
Lipase and amylase activity is crucial to the diagnosis of
acute pancreatitis.20 According to the updated Atlanta classifica-
tion,20 2 of the following 3 features are required: (1) abdominal
pain consistent with acute pancreatitis (acute onset of a persistent,
severe, epigastric pain often radiating to the back), (2) serum li-
pase (or amylase) activity at least 3 times greater than the upper
limit of normal (ULN), and (3) characteristic findings of acute
pancreatitis on contrast-enhanced computed tomography and less
commonly magnetic resonance imaging or transabdominal ultra-
sonography. Therefore, it is important to further define the in-
fluence of type 2 diabetes on these enzymes. The LEADER
(Liraglutide Effect and Action in Diabetes: Evaluation of Cardio-
vascular Outcome Results) trial includes over 9000 subjects with
type 2 diabetes who are randomized to receive liraglutide or pla-
cebo. The purpose of the current study is to assess baseline amy-
lase and lipase activity in the LEADER population. We believe
that this is the largest study of lipase and amylase activity in sub-
jects with type 2 diabetes.
MATERIALS AND METHODS
Subjects and Study Design
The LEADER trial is an international double-blind placebo-
controlled trial currently evaluating the cardiovascular safety of
liraglutide (www.clinicaltrials.gov; NCT01179048). There are
9340 subjects with type 2 diabetes at high risk for cardiovascular
events (with or without existing cardiovascular disease) enrolled
at 410 centers worldwide and randomized 1:1 to liraglutide or
placebo. Subjects will be followed for a minimum of 3.5 years.
Baseline characteristics of subjects enrolled in LEADER have
been described elsewhere.21 Briefly, subjects with type 2 diabetes
and elevated cardiovascular risk who were either drug-naive or
treated with 1 or more antihyperglycemic drugs were screened.
Subjects treated with GLP-1 receptor agonists or DPP-4 inhibitors
were excluded. Medical history, including history of pancreatitis
and/or gallstone disease, was obtained. Enrollment of subjects
with severely reduced estimated glomerular filtration rate (eGFR
<30 mL/min per 1.73 m2) was limited to a maximum of 220,
whereas no similar limit was applied to subjects with mod-
erately reduced eGFR (30–60 mL/min per 1.73 m2). After a
2-week run-in phase, subjects were randomized in double-blind
fashion to receive either liraglutide (0.6 mg up to amaximumdose
of 1.8 mg) once daily or equivalent placebo as an add-on to their
baseline treatment. After randomization, study visits occur at
months 1, 3, and 6 and every 6 months thereafter until termination
of the trial. Subjects are followed for up to 5 years. Secondary and
safety end points include, among others, the incidence of acute
pancreatitis, acute gallstone disease, and changes in serum lipase
and amylase. Enrollment commenced in September 2010 and was
completed in April 2012. Each enrolling center's institutional re-
view board approved the study.
Lipase and Amylase Screening and Monitoring
Lipase and amylase activity is measured at baseline and
months 6 and 12. Assessments are to be repeated annually (for
up to 5 years) until termination of the trial, with a final measure-
ment at the end of treatment. Serum pancreatic lipase and total
amylase activity is measured in the fasting state in all subjects
using an enzymatic colorimetric assay (Roche Diagnostics, Mann-
heim, Germany) performed by a central laboratory (ICON PLC,
Dublin, Ireland). None of the subjects had symptoms suggesting
acute pancreatitis at the time of baseline blood drawing. The
ULN for this assay is set at 63 U/L for lipase and 100 U/L for
amylase. Neither limit is adjusted for subjectswith type 2 diabetes.
Per protocol, more frequent measurements of lipase and amylase
activity are to be conducted locally in cases of persistent severe
abdominal pain leading to a suspicion of acute pancreatitis.
Statistical Analysis
The distribution of both lipase and amylase values was right-
skewed; therefore a logarithmic transformation was applied before
analysis. Explanatory factors were prespecified and included sex,
age, body mass index (BMI), smoking status, race, duration of di-
abetes, glycemic control (HbA1c), diabetes pretreatment, eGFR
(modified diet in renal disease formula), autoimmune disease, thy-
roid disease, lipid levels, and use of certain medications (proton
pump inhibitors, β-blockers, H2 receptor antagonists, and gluco-
corticoids). A multivariable linear normal analysis of covariance
model was created, with the logarithmically transformed lipase
and amylase values as dependent variables. The effect of each co-
variate was first derived on the log scale and then exponentially
transformed to obtain an interpretation as relative activity of lipase
and amylase. Effects of each factor are therefore adjusted to the set
of all other factors and expressed in relative terms, with an effect
equal to 1.0 representing “neutral” (also expressed as percent
change = 0%). All analyses were performed using SAS version
9.3 (SAS Institute, Cary, NC).
All authors had access to the study data and reviewed and ap-
proved the final article.
RESULTS
Baseline characteristics of the LEADER population strati-
fied by sex are presented in Table 1. No subjects had symptoms
of pancreatitis at baseline, and lipase activity was available in
99.3% of all subjects (n = 9273). The distribution of lipase values
is depicted in Figure 1A. Mean (SD) and median (interquartile
range) values were 47.5 (43.7) U/L and 38.3 (28.2–53.9) U/L, re-
spectively. Baseline amylasewas available in 99.7% of all subjects
(n = 9309), with mean (SD) and median values of 66.2 (36.3) and
59.0 (44.0–79.0) U/L, respectively (Fig. 1B). There were 9273
subjects with both valid amylase and lipase values.
Among all subjects with available baseline data for both en-
zymes, 16.6% (n = 1540) and 11.8% (n = 1094), respectively, had
lipase and amylase activity above the ULN.Measurements greater
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than 3 times the ULN for lipase were seen in 1.2% of subjects and
0.2% for amylase (Figs. 1A, B; Table 2).
Results of the same multivariable regression model performed
separately for lipase and amylase are presented in Table 3A and B.
Severely reduced eGFR (<30mL/min per 1.73 m2, corresponding
to the National Kidney Foundation Kidney Disease Outcomes
Quality Initiative chronic kidney disease [CKD] stage 4–5) was
associated with the largest effect on increasing lipase and amylase
TABLE 1. Baseline Demographics
Total (N = 9340) Female (n = 3337) Male (n = 6003)
Age, y 64.3 (7.2); 64.0 64.4 (7.2); 64.0 64.2 (7.3); 64.0
Body weight, kg 91.8 (21.0); 89.9 84.7 (19.5); 82.4 95.7 (20.8); 93.2
BMI, kg/m2 32.5 (6.3); 31.7 33.6 (6.8); 32.8 31.9 (5.9); 31.2
HbA1c, % 8.7 (1.5); 8.3 8.8 (1.6); 8.4 8.6 (1.5); 8.2
Diabetes duration, y 12.7 (8.0); 11.3 13.3 (8.3); 11.8 12.4 (7.8); 11.1
Blood pressure, mm Hg
Systolic 137.7 (18.6); 137.0 139.1 (19.2); 138.0 136.9 (18.2); 136.0
Diastolic 77.9 (10.5); 78.5 78.1 (10.7); 79.0 77.8 (10.3); 78.5
Heart rate, beats per minute 73.2 (11.4); 72.0 74.4 (10.9); 74.0 72.5 (11.6); 72.0
eGFR, mL/min per 1.73 m2
<30 177 (1.9) 76 (2.3) 101 (1.7)
30–59 1854 (19.9) 700 (21.0) 1154 (19.2)
60–89 3860 (41.3) 1353 (40.5) 2507 (41.8)
≥90 3447 (36.9) 1207 (36.2) 2240 (37.3)
Glucose lowering treatment
Diet or no treatment 504 (5.4) 128 (5.3) 376 (5.5)
Insulin alone 665 (7.1) 279 (8.4) 386 (6.4)
Oral glucose lowering* 4931 (52.8) 1687 (50.6) 3244 (54.0)
Oral glucose lowering + insulin 3240 (34.7) 1195 (35.8) 2045 (34.1)
Prior cardiovascular disease 7592 (81.3) 2544 (76.2) 5048 (84.1)
No. oral antihyperglycemic medications used
1 1917 (20.5) 679 (20.3) 1238 (20.6)
2 2686 (28.8) 914 (27.4) 1772 (29.5)
>2 328 (3.5) 94 (2.8) 234 (3.9)
Smoking
Current 1130 (12.1) 281 (8.4) 849 (14.1)
Previous 4337 (46.4) 926 (27.7) 3411 (56.8)
Never 3873 (41.5) 2130 (63.8) 1743 (29.0)
Data shown are mean (SD); median for continuous variables and n (%) for groupings.
*Not used in combination with insulin.
FIGURE 1. Distribution of (A) lipase and (B) amylase values in all randomized subjects. Horizontal lines (from lowest to highest value on y-axis)
denote 1, 2, 3, and 10 times ULN values.
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activity. There were no effects on either lipase or amylase activ-
ity from history of CVD, thyroid disease, autoimmune disease,
pancreatitis, or gallstones; diabetes duration; or glucocorticoid
use. Several characteristics unrelated to eGFR were associated
with smaller but statistically significant changes in serum lipase
and amylase activity. For lipase, Asian race, higher HbA1c, higher
serum triglyceride concentrations, presence of diabetic nephropa-
thy, and treatment with oral antihyperglycemic drugs were associ-
ated with increasing activity, whereas female sex, black race,
increasing age, higher BMI, use of proton pump inhibitors, higher
serum low density lipoprotein (LDL) cholesterol concentrations,
and insulin treatment were associated with decreasing activity.
For amylase, Asian and black races, higher serum high density
lipoprotein (HDL) cholesterol concentrations, and presence of di-
abetic nephropathywere associatedwith increasing activity, whereas
female sex, history of smoking, increasing age, increasing BMI,
increasing HbA1c, history of cholecystitis, gallstone disease, and
use of β-blockers, H2 receptor antagonists, and proton pump in-
hibitors were associated with decreasing activity.
The distribution of baseline lipase and amylase values by
eGFR in subjects with known values for eGFR, lipase, and amy-
lase (n = 9271) is shown in Table 2. There was an association be-
tween progressive eGFR reductions and elevations in both (either
>ULN or >3 ULN). However, a majority of the 177 subjects
with eGFR less than 30 mL/min per 1.73 m2 (corresponding to
the National Kidney Foundation Kidney Disease Outcomes Qual-
ity Initiative CKD stage 4–5) had normal lipase (65%) and normal
amylase (73%) activity. Of those subjects with normal eGFR
(≥90 mL/min per 1.73 m2), 12.2% had elevated lipase and 7.7%
had elevated amylase activity.
Table 4 analyzes subjects with normal or elevated levels of
activity in both, one enzyme, or the other. Among subjects with el-
evations in either enzyme (22.7%), approximately one quarter had
elevated amylase level with normal lipase, approximately one half
had elevated lipase level with normal amylase, and approximately
one quarter had both elevated lipase and amylase levels.
Table 5 reviews data compiled in recent publications evaluat-
ing baseline lipase and amylase in subjects with type 2 diabetes,
either unrelated to GLP-1 receptor agonists or DPP-4 inhibitor
therapy or before randomization to GLP-1 receptor agonists or
DPP-4 inhibitors. The present study contains the largest cohort,
whereas the proportions of type 2 diabetes subjects with elevated
activity in either enzyme are consistent with previous work.
DISCUSSION
In this report of baseline data from the LEADER trial, nearly
one quarter (22.7%) of subjects with type 2 diabetes had elevated
levels of lipase and/or amylase activity above ULN. The propor-
tions of subjects with elevated serum lipase (16.6%) and amylase
(11.8%) activity were consistent with findings from previous re-
ports in type 2 diabetes,14–17 and elevations above 3 times the
ULN were seen in 1.2% of subjects for lipase and 0.2% for amy-
lase. To our knowledge, this is the largest study (N = 9340) of
lipase and amylase activity in a population of type 2 diabetes
mellitus. Logistic regression indicated that worsening eGFR was
the most prominent factor influencing lipase and amylase activity.
An eGFR less than 30 mL/min per 1.73 m2 (corresponding to
CKD stage 4–5) was associated with higher serum lipase and am-
ylase activity and greater proportions of subjects with elevations
in either enzyme, findings recognized in other studies.22 However,
of those subjects with normal renal function (eGFR ≥90 mL/min
per 1.73 m2), 12.2% had elevated levels of lipase and 7.7% had el-
evated levels of amylase activity. Other factors shown to have a
smaller impact on either increasing or decreasing lipase or amy-
lase activity included certain drugs (proton pump inhibitors, insu-
lin, and oral antihyperglycemics), BMI, HbA1c level, age, and
race. Risk factors, known to be associated with pancreatitis, such
as a history of pancreatitis or gallstones, did not seem to affect
baseline activity of either lipase or amylase. Other environmental
factors such as alcohol intake and smoking have been described
as risk factors for the development of pancreatitis.23 Although a
history of alcohol consumption was not systematically collected
for the present population, smoking was analyzed and did not
have an independent effect on pancreatic enzyme activity.
It is unclear why lipase and amylase activity is elevated in a
significant portion of subjects with type 2 diabetes. To understand
these findings, the complex physiologic nature of these biochem-
ical markers requires comment. It is known that there are many
sources of amylase and lipase in the human body. Amylase exists
TABLE 2. Distribution of Baseline Lipase and Amylase Values by eGFR (mL/min per 1.73 m2) in Subjects With Known eGFR, Lipase,
and Amylase Measures (n = 9271)
A. Lipase, U/L
eGFR >ULN >3 ULN
<30 (n = 177) 35.03 1.69
30–59 (n = 1840) 24.02 1.25
60–89 (n = 3837) 16.13 1.49
≥90 (n = 3417) 12.17 0.85
Total (n = 9271) 16.60 1.21
ULN = 63 U/L
B. Amylase
eGFR >ULN >3 ULN
<30 (n = 177) 26.55 0.57
30–59 (n = 1840) 18.70 0.16
60–89 (n = 3837) 11.31 0.26
≥90 (n = 3417) 7.72 0.06
Total (n = 9271) 11.75 0.17
ULN = 100 U/L
Data are presented as percent.
Steinberg et al Pancreas • Volume 00, Number 00, Month 2014
4 www.pancreasjournal.com © 2014 Lippincott Williams & Wilkins
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
TABLE 3. Multivariable Log-Linear Regression Models Performed Separately for Lipase and Amylase*
Effect 95% Confidence Limits P Percentage Change
A. Lipase
eGFR, per 10 mL/min per 1.73 m2
<30 1.540 1.413–1.678 <0.0001 54.0
30–59 1.287 1.243–1.334 <0.0001 28.7
60–89 1.121 1.093–1.150 <0.0001 12.1
≥90† 1.000
Sex
Female 0.955 0.931–0.980 0.0005 −4.5
Male† 1.000
Smoking 0.972 0.939–1.006 0.1052 −2.8
Race
Asian 1.018 0.979–1.059 0.3659 1.8
Black 0.951 0.913–0.991 0.0178 −4.9
Other 1.026 0.972–1.084 0.3487 2.6
White† 1.000
Prior cardiovascular disease
No 1.011 0.979–1.044 0.5227 1.1
Yes† 1.000 — — —
Age, per 10-year increment 0.942 0.925–0.958 <0.0001 −5.8
BMI, per 10-kg/m2 increment 0.942 0.924–0.960 <0.0001 −5.8
HbA1c, per % increment 1.018 1.011–1.026 <0.0001 1.8
Diabetes duration, per year increment 0.999 0.998–1.001 0.2006 −0.1
Autoimmune disorder 1.040 0.974–1.111 0.2417 4.0
Thyroid disease 0.971 0.940–1.003 0.0792 −2.9
β-Blocker use 1.015 0.991–1.039 0.2189 1.5
H2 receptor antagonist use 0.980 0.921–1.043 0.5254 −2.0
Proton pump inhibitor use 0.896 0.871–0.921 <0.0001 −10.4
Glucocorticoid use 0.947 0.883–1.017 0.1346 −5.3
LDL cholesterol, per mmol/L increment 0.967 0.955–0.979 <0.0001 −3.3
HDL cholesterol, per mmol/L increment 1.018 0.978–1.059 0.3933 1.8
Triglycerides, per mmol/L increment 1.048 1.033–1.063 <0.0001 4.8
History of pancreatitis 1.000 0.932–1.073 0.9940 −0.0
History of cholecystitis 0.965 0.921–1.012 0.1397 −3.5
History of diabetic nephropathy 1.040 1.014–1.066 0.0025 4.0
History of gallstones 1.032 0.995–1.071 0.0938 3.2
Diabetes pretreatment
Insulin + oral antihyperglycemics 1.024 0.972–1.078 0.3776 2.4
Insulin only 0.869 0.816–0.926 <0.0001 −13.1
Oral antihyperglycemics only 1.114 1.059–1.171 <0.0001 11.4
None/diet† 1.000 — — —
B. Amylase
eGFR, per 10 mL/min per 1.73 m2
<30 1.466 1.368–1.572 <0.0001 46.6
30–59 1.261 1.225–1.297 <0.0001 26.1
60–89 1.114 1.091–1.137 <0.0001 11.4
≥90† 1.000
Sex
Female 0.891 0.873–0.910 <0.0001 −10.9
Male† 1.000
Smoking 0.968 0.941–0.995 0.0201 −3.2
Race
Asian 1.158 1.122–1.196 <0.0001 15.8
Black 1.358 1.314–1.404 <0.0001 35.8
(continued on next page)
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in 2 isoenzyme forms: p-amylase (mostly originating from the
pancreas) and s-amylase (mostly originating from the salivary
glands). However, other sources in the body can contain various
mixtures of both forms, including the fallopian tubes, thyroid,
small intestine, liver, placenta, testis, skeletal muscle, and spleen,
as well as various tumors.24–29 In the asymptomatic subject, se-
rum amylase is made up of a mixture of p-amylase (approximately
40%) and s-amylase (approximately 60%). In acute pancreatitis,
the predominant isoenzyme in the serum is p-amylase. However,
p-amylase level has been reported to be markedly elevated in other
nonpancreatic acute conditions such as ovarian cyst rupture.30
Several types of lipase are also present in the human body, includ-
ing gastric, pancreatic, hepatic, endothelial, and muscle.31–33 The
pancreas itself contain several different lipases, including pancre-
atic triglyceride lipase, pancreatic lipase-related proteins 1 and 2,
carboxyl ester lipase, and phospholipase A2.34 It is generally
TABLE 4. Distribution of Lipase and Amylase Activity According to eGFR (mL/min per 1.73 m2)
Lipase Normal,
Amylase Normal
Lipase Normal,
Amylase >ULN
Amylase Normal,
Lipase >ULN
Amylase >ULN,
Lipase >ULN
eGFR
<30 (n = 177) 95 (53.7) 20 (11.3) 35 (19.8) 27 (15.3)
30–59 (n = 1840) 1221 (66.4) 177 (9.6) 275 (15.0) 167 (9.1)
60–89 (n = 3837) 2998 (78.1) 220 (5.7) 405 (10.6) 214 (5.6)
≥90 (n = 3417) 2852 (83.5) 149 (4.4) 301 (8.8) 115 (3.4)
Total (n = 9271) 7166 (77.3) 566 (6.1) 1016 (11.0) 523 (5.6)
Data are presented as n (%).
*ULN = 63 U/L
†ULN = 100 U/L
TABLE 3. (Continued)
Effect 95% Confidence Limits P Percentage Change
B. Amylase
Race
Other 1.168 1.118–1.221 <0.0001 16.8
White† 1.000
Prior cardiovascular disease
No 0.989 0.964–1.015 0.4094 −1.1
Yes† 1.000 — — —
Age, per 10-year increment 0.981 0.967–0.995 0.0071 −1.9
BMI, per 10-kg/m2 increment 0.853 0.840–0.866 <0.0001 −14.7
HbA1c, per % increment 0.984 0.978–0.990 <0.0001 −1.6
Diabetes duration, per year increment 1.000 0.999–1.001 0.7723 0.0
Autoimmune disorder 1.012 0.959–1.067 0.6742 1.2
Thyroid disease 0.980 0.955–1.006 0.1390 −2.0
β-Blocker use 0.967 0.949–0.985 0.0005 −3.3
H2 receptor antagonist use 0.945 0.899–0.994 0.0283 −5.5
Proton pump inhibitor use 0.934 0.913–0.955 <0.0001 −6.6
Glucocorticoid use 0.976 0.921–1.033 0.4004 −2.4
LDL cholesterol, per mmol/L increment 0.988 0.978–0.998 0.0201 −1.2
HDL cholesterol, per mmol/L increment 1.079 1.045–1.115 <0.0001 7.9
Triglycerides, per mmol/L increment 0.994 0.983–1.006 0.3214 −0.6
History of pancreatitis 0.970 0.916–1.027 0.2923 −3.0
History of choleosystitis 0.937 0.902–0.974 0.0009 −6.3
History of diabetic nephropathy 1.044 1.023–1.066 <0.0001 4.4
History of gallstones 1.006 0.976–1.036 0.7160 0.6
Diabetes pretreatment
Insulin + oral antihyperglycemics 1.033 0.991–1.077 0.1245 3.3
Insulin only 0.966 0.918–1.017 0.1848 −3.4
Oral antihyperglycemics only 1.040 0.998–1.083 0.0591 4.0
None/diet† 1.000
*Effective number of subjects contributing to analysis: n = 8824 (no missing values allowed).
†Reference.
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assumed that basal serum lipase is of pancreatic origin. However,
the actual proportion of basal serum lipase from other sources is
unknown. The lipase assay in LEADER uses colipase and bile
salts and hence is thought to be specific for pancreatic lipase activ-
ity. However, some experts question whether these assays
can truly distinguish pancreatic from nonpancreatic lipases (per-
sonal communication: Mark Lowe, MD, PhD, vice-chairman
and professor of pediatrics at University of Pittsburgh School of
Medicine).
Lipase and amylase are synthesized in the pancreatic acinar
cell, packaged in zymogen granules, and thought to reach the
blood stream by leakage of these enzymes from the basal lateral
membrane of the acinus into the surrounding capillaries or via
the pancreatic lymph with drainage through the thoracic duct.31,35
Secretory studies in animals and humans demonstrate an effect of
a high-carbohydrate or high-fat diet on the composition of amy-
lase and lipase in these granules.36,37 However, it is unknown
whether fasting or food consumption has an effect on levels of
serum activity for either enzyme. Amylase is filtered by the renal
glomerulus and excreted into urine where it can be measured.
Lipase is also filtered at the glomerulus but almost completely
reabsorbed by the renal tubules, leaving negligible amounts of
lipase in the urine.38–40 Rat studies suggest that amylase, and par-
ticularly lipase, is degraded by the renal tubules; however, there
are no data on this process in humans.40
Given the limited knowledge on the origins and excretion/
degradation of serum amylase and lipase, there are several possi-
ble explanations for elevated activity in the diabetic population.
Our data confirm prior observations that reduced eGFR raises
serum lipase and amylase activity. Possible mechanisms include
reduced glomerular filtration, a change in tubular reabsorption,
degradation of the enzymes, or all of these factors. It should be
noted, however, that reduced eGFR does not affect both enzymes
equally. In the group with eGFR less than 30 mL/min per 1.73 m2
(CKD stage 4–5), amylase activity alone was elevated in 11%,
lipase activity alone was elevated in 19.8%, and both were ele-
vated in 15.3% (Table 4). Neither these findings nor our finding
that more than one half of the subjects with eGFR less than
30 mL/min per 1.73 m2 had normal lipase and amylase activity
can be explained on the basis of known mechanisms.
It is unclear what is driving elevated lipase and amylase ac-
tivity unrelated to kidney function (12% and 7% of the entire
cohort, respectively). Subclinical pancreatic inflammation may
be one explanation. Prior studies suggest that subclinical chronic
pancreatitis may be increased in subjects with type 2 diabetes. In
an asymptomatic diabetes population, Hardt and colleagues41
showed that 35% (compared with 18% in controls) of subjects
with diabetes had a low fecal elastase concentration, which is
thought to be a marker of pancreatic insufficiency or chronic pan-
creatitis. One autopsy study revealed that subjects with diabetes
had a greater level of pancreatic fibrosis and evidence of chronic
pancreatitis than controls.42 However, if pancreatic inflamma-
tion explained the enzyme elevations, it might be expected that
lipase and amylase activity would be elevated to a similar degree.
Nevertheless, our data, as well as that from others,13–18 indicate
that lipase activity elevations predominate over amylase in the
percentage of subjects affected. In addition, amylase activity is
elevated about 25% of the time without an elevation in lipase
(Table 4).
Because amylase and lipase come from other potential sites
(gastric, hepatic, endothelial, muscle), it is possible that these se-
rum enzymes in diabetesmay originate in areas other than the pan-
creas. It is also possible that diabetes—or the drugs that subjects
with type 2 diabetes take—may cause changes in the secretion
or excretion/degradation of these enzymes by the kidney that
may also lead to elevations. An increased glucose concentration,
as found in poorly controlled diabetes or ketoacidosis, has previ-
ously been reported to affect enzyme activity43; however, this
finding in relation to HbA1c could not be confirmed.16 In our
population, a higher HbA1c was related to higher lipase but lower
amylase activity. The impact of confounding risk factors that may
be present andmore common in a type 2 diabetes population, such
as cholelithiasis or hypertriglyceridemia, also does not provide a
clear picture. Although some of these factors showed significant
associations due to the large sample size in LEADER, the effect
sizes were small and presented no consistent trend (eg, HbA1c).
The present study is strengthened by its robust sample size,
consisting of the largest study to date of lipase and amylase in a
type 2 diabetes population. On the other hand, LEADER specifi-
cally enrolled subjects at high cardiovascular risk, potentially lim-
iting the generalizability of our findings. However, there is no
reason to expect that cardiovascular disease per se would change
pancreatic enzyme activity. Furthermore, similar elevations in li-
pase and amylase were noted in other studies that did not specifi-
cally include subjects at high cardiovascular risk.15,16,18 Our study
measured total amylase and not pancreatic (p-) amylase; thus dif-
ferent findings may have resulted from use of this assay. Others
have in fact measured p-amylase in subjects with diabetes and
found that 6% had an elevation, approximately one half that of
our results.16
In conclusion, our study shows that among subjects with
type 2 diabetes, 16.6% had elevated lipase (including 1.2% that
TABLE 5. Other Studies Reporting Elevated Lipase and Amylase Levels in Subjects With Type 2 Diabetes
Lipase Amylase
>ULN >3 ULN >ULN >3 ULN
Lando et al15 (n = 33) 18.0 NR 3.0 NR
Bastyr et al17 (n = 440) 13.0 NR 5.0 NR
Malloy et al16 (n = 514) 13.0 1.0 6.0 0.5
Steinberg et al18 (n = 987) 20.4 2.1 8.5 0.1
Exenatide LAR13 11.4* NR 4.8† NR
LEADER (present study) (n = 9273) 16.6 1.2 11.7 0.17
Data are presented as percent of the total population, ULN.
*Subjects with lipase measurements (n = 2153).
†Subjects with amylase measurements (n = 1199).
NR, not recorded.
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have a greater than 3-fold elevation) and 11.8% had elevated
amylase activity (0.2% >3-fold elevated). Although it may be
the single most important parameter responsible for some of the
elevations, reduced kidney function is not responsible for most.
Other significant causes remain unknown. Because pancreatic
enzyme elevations (especially a 3-fold elevation) are crucial for
the diagnosis of acute pancreatitis (along with significant upper
abdominal pain and positive imaging with computed tomography,
magnetic resonance imaging, or abdominal ultrasound),16 it is
important for the gastroenterologist to be aware of the pitfalls of
these laboratory studies in subjects with diabetes. In addition, cer-
tain antidiabetic drugs such as GLP-1 receptor agonists may raise
pancreatic enzymes above baseline, further confusing the enzyme
picture.16 Therefore, it is important for the clinician to pay extra
attention to clinical symptoms and imaging in the diabetic popula-
tion when considering the diagnosis of acute pancreatitis.
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